Abstract

With the evolving understanding of the interaction between tumor and the immune system, novel therapies with sophisticated mechanisms of action are establishing themselves as the standards of care. In human cancer, the immune system plays a double edged sword with both protecting against tumor development as well as promoting tumor growth. In recent times innumerable practice-changing clinical studies have being reported on immunotherapy. In this review article, we highlight the recently approved immunotherapy and chemotherapy combination in adjuvant and 1st line metastatic setting in various solid tumors except renal cell carcinoma and melanoma.

Keywords: Gastroesophageal; Chemoradiotherapy; Pembrolizumab; Nivolumab